XTL Biopharmaceuticals Ltd. Share Price Nasdaq
Equities
XTLB
US98386D3070
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.6 USD | +0.39% | +1.56% | +157.40% |
29/04 | Top Premarket Gainers | MT |
21/03 | XTL Biopharmaceuticals Ltd. announced that it expects to receive $1.5 million in funding | CI |
Sales 2021 | - | Sales 2022 | - | Capitalization | 6.36M 531M |
---|---|---|---|---|---|
Net income 2021 | - 0 | Net income 2022 | -1M -83.46M | EV / Sales 2021 | - |
Net cash position 2021 | 6.13M 511M | Net cash position 2022 | 3.72M 311M | EV / Sales 2022 | - |
P/E ratio 2021 |
39.2
x | P/E ratio 2022 |
-4.72
x | Employees | 5 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 93.3% |
1 day | +0.39% | ||
1 week | +1.56% | ||
Current month | +0.39% | ||
1 month | -13.62% | ||
3 months | +188.95% | ||
6 months | +198.82% | ||
Current year | +157.40% |
Managers | Title | Age | Since |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 30/14/30 |
Itay Weinstein
DFI | Director of Finance/CFO | 52 | 01/99/01 |
Doron Turgeman
CHM | Chairman | 56 | 30/14/30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 30/14/30 |
Director/Board Member | 57 | 29/20/29 | |
Director/Board Member | 53 | 01/17/01 |
Date | Price | Change | Volume |
---|---|---|---|
02/24/02 | 2.6 | +0.39% | 9 177 |
30/24/30 | 2.59 | +7.02% | 21,356 |
29/24/29 | 2.42 | -0.08% | 5,292 |
26/24/26 | 2.422 | +0.92% | 5,253 |
25/24/25 | 2.4 | -6.25% | 6,198 |
Delayed Quote Nasdaq, May 02, 2024 at 01:30 am IST
More quotes1st Jan change | Capi. | |
---|---|---|
+0.67% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+6.55% | 24.63B | |
-21.66% | 18.2B | |
+29.96% | 12.01B | |
-1.57% | 11.76B | |
+16.03% | 10.4B | |
-4.80% | 9.94B |
- Stock Market
- Equities
- XTLB Stock
- XTLB Stock